Topic

Aetna (CVS Health)

A collection of 1133 issues

Getting Ultomiris (Ravulizumab) Covered by Aetna CVS Health in California: Forms, Appeals, and Alternative Options

Answer Box: Fast Track to Ultomiris Coverage To get Ultomiris (ravulizumab) covered by Aetna CVS Health in California: Submit the Ultomiris Precertification Request form with complete clinical documentation showing FDA-approved indication, failed alternatives, and vaccination records. If denied, file internal appeal within 60 days, then request California Independent Medical Review
6 min read

Renewing Zokinvy (lonafarnib) Approval with Aetna CVS Health in Virginia: Complete Guide to Prior Authorization Renewal, Appeals, and Bridge Options

Quick Answer: Renewing Your Zokinvy (lonafarnib) Approval Aetna CVS Health typically requires annual prior authorization renewal for Zokinvy (lonafarnib) with updated clinical documentation showing ongoing medical necessity and benefit. Submit your renewal request 30-45 days before your current PA expires to avoid treatment interruption. Required documents include: genetic testing confirmation,
7 min read

Do You Qualify for Vitrakvi (Larotrectinib) Coverage by Aetna (CVS Health) in Ohio? Complete Decision Tree & Appeals Guide

Quick Answer: Your Path to Vitrakvi (Larotrectinib) Coverage in Ohio To qualify for Vitrakvi (larotrectinib) coverage through Aetna (CVS Health) in Ohio, you need: (1) documented NTRK gene fusion-positive solid tumor, (2) metastatic or unresectable disease, and (3) prescription by an in-network oncologist. Fastest approval path: Submit prior authorization through
5 min read

How to Get Sylvant (siltuximab) Covered by Aetna (CVS Health) in North Carolina: Complete Prior Authorization and Appeals Guide

Answer Box: Getting Sylvant (siltuximab) Covered by Aetna (CVS Health) in North Carolina Sylvant requires prior authorization from Aetna (CVS Health) for idiopathic multicentric Castleman disease (iMCD). The fastest path: ensure your oncologist submits complete documentation showing HIV-negative/HHV-8-negative status, multicentric pathology, and active disease. If denied, North Carolina'
6 min read